Soligenix Inc., of Princeton, N.J., published data from an investigator-initiated Phase II trial of orBec (oral beclomethasone dipropionate) showing the drug was well tolerated but did not achieve statistical significance in reducing graft-vs.-host disease (GVHD) following hematopoietic cell transplantation, as previously reported. The data were published in Biology of Blood and Marrow Transplantation. Soligenix halted a Phase III GVHD trial in September after an interim analysis showed it was unlikely to meet its endpoint.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter